RNA modification‐related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single‐cell sequencing analysis

The clinical outcomes of osteosarcoma are relatively dismal. As immunotherapy has revolutionized treatment for solid tumors, exploring novel immunotherapy‐related therapeutic targets for osteosarcoma is important. In this study, we aimed to establish the connection between RNA modification and immun...

Full description

Saved in:
Bibliographic Details
Published in:Environmental toxicology 2024-10, Vol.39 (10), p.4547-4561
Main Authors: Qin, Haocheng, Yang, Shu, Feng, Zhennan, Wu, Song, Cai, Ting, Xie, Zijing, Hu, Hai
Format: Article
Language:English
Subjects:
Algorithms
Bone Neoplasms - drug therapy
Bone Neoplasms - genetics
Bone Neoplasms - immunology
Bone Neoplasms - pathology
Cell Line, Tumor
EIF4G2
Eukaryotic Initiation Factor-4G - genetics
Gene sequencing
Humans
Immunotherapy
Immunotherapy - methods
Leukocyte migration
Machine learning
Macrophages
Neoplasms
Network analysis
Nucleic acids
Osteosarcoma
Osteosarcoma - drug therapy
Osteosarcoma - genetics
Osteosarcoma - immunology
Osteosarcoma - pathology
Ribonucleic acid
RNA
RNA modification
Sequence analysis
Sequencing
Single-Cell Analysis
single‐cell sequencing analysis
Solid tumors
Therapeutic targets
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical outcomes of osteosarcoma are relatively dismal. As immunotherapy has revolutionized treatment for solid tumors, exploring novel immunotherapy‐related therapeutic targets for osteosarcoma is important. In this study, we aimed to establish the connection between RNA modification and immunotherapy in osteosarcoma to identify novel therapeutic targets. An RNA modification‐related signature was first developed using weight gene correlation network analysis and a machine‐learning algorithm, random forest. The signature's prognostic value, drug prediction, and immune characteristics were analyzed. EIF4G2 from the signature was next identified as a critical immunotherapy determinant. EIF4G2 could also promote tumor proliferation, migration, and M2 macrophage migration by single‐cell sequencing analysis and in vitro validation. Our signature and EIF4G2 are expected to provide valuable insights into the clinical management of osteosarcoma.
ISSN:1520-4081
1522-7278
1522-7278
DOI:10.1002/tox.24261